Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial

Nicole Mittmann; Heather-Jane Au; Dongsheng Tu; Christopher O'Callaghan; Pierre Isogai; Christos Karapetis; John Zalcberg; William Evans; Malcolm Moore; Jehan Siddiqui; Brian Findlay; Bruce Colwell; R. Simes; Peter Gibbs; Matthew Links; Niall Tebbutt; Derek Jonker

Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial

Nicole Mittmann, Heather-Jane Au, Dongsheng Tu, Christopher O'Callaghan, Pierre Isogai, Christos Karapetis, John Zalcberg, William Evans, Malcolm Moore, Jehan Siddiqui, Brian Findlay, Bruce Colwell, R. Simes, Peter Gibbs, Matthew Links, Niall Tebbutt, Derek Jonker

Research output: Contribution to journal › Article › peer-review

108 Citations (Scopus)

Original language	English
Pages (from-to)	1182-1192
Number of pages	11
Journal	Journal of The National Cancer Institute
Volume	101
Issue number	17
Publication status	Published - 2009

Cite this

Mittmann, N., Au, H-J., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Findlay, B., Colwell, B., Simes, R., Gibbs, P., Links, M., Tebbutt, N., & Jonker, D. (2009). Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial. Journal of The National Cancer Institute, 101(17), 1182-1192.

@article{42a984daf4904ad6bba542f1219841c8,

title = "Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial",

author = "Nicole Mittmann and Heather-Jane Au and Dongsheng Tu and Christopher O'Callaghan and Pierre Isogai and Christos Karapetis and John Zalcberg and William Evans and Malcolm Moore and Jehan Siddiqui and Brian Findlay and Bruce Colwell and R. Simes and Peter Gibbs and Matthew Links and Niall Tebbutt and Derek Jonker",

year = "2009",

language = "English",

volume = "101",

pages = "1182--1192",

journal = "Journal of The National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "17",

}

Mittmann, N, Au, H-J, Tu, D, O'Callaghan, C, Isogai, P, Karapetis, C, Zalcberg, J, Evans, W, Moore, M, Siddiqui, J, Findlay, B, Colwell, B, Simes, R, Gibbs, P, Links, M, Tebbutt, N & Jonker, D 2009, 'Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial', Journal of The National Cancer Institute, vol. 101, no. 17, pp. 1182-1192.

Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial. / Mittmann, Nicole; Au, Heather-Jane; Tu, Dongsheng et al.

In: Journal of The National Cancer Institute, Vol. 101, No. 17, 2009, p. 1182-1192.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prospective cost-effectiveness analysis of Cetuximab in metastatic colorectal cancer: evaluation of national cancer institute of Canada clinical trials group CO.17 trial

AU - Mittmann, Nicole

AU - Au, Heather-Jane

AU - Tu, Dongsheng

AU - O'Callaghan, Christopher

AU - Isogai, Pierre

AU - Karapetis, Christos

AU - Zalcberg, John

AU - Evans, William

AU - Moore, Malcolm

AU - Siddiqui, Jehan

AU - Findlay, Brian

AU - Colwell, Bruce

AU - Simes, R.

AU - Gibbs, Peter

AU - Links, Matthew

AU - Tebbutt, Niall

AU - Jonker, Derek

PY - 2009

Y1 - 2009

M3 - Article

SN - 0027-8874

VL - 101

SP - 1182

EP - 1192

JO - Journal of The National Cancer Institute

JF - Journal of The National Cancer Institute

IS - 17

ER -